期刊文献+

何塞停治疗晚期乳腺癌的研究现状

Herceptin (trastuzamab) for Treatment of Advanced Breast Cancer.
下载PDF
导出
摘要 何塞停(Herceptin)是一种人性化单克隆抗体,能特异性地作用于HER-2受体过度表达的乳腺癌细胞,限制原癌基因HER-2/neu的过度表达,抑制肿瘤细胞生长,增强化疗药物疗效并减轻其毒副作用.临床上单独或联合用于转移性乳腺癌的治疗已取得了良好效果,并且具有毒副作用小,使用安全的优点..本文对Herceptin的理化性状、作用机制及临床应用进行了综述.肿瘤防治杂志,2001,8(特)
出处 《中华肿瘤防治杂志》 CAS 2001年第z1期-,共5页 Chinese Journal of Cancer Prevention and Treatment
  • 相关文献

参考文献37

  • 1[1]Weiner LM.Monoclonal antibody of cancer. [J]Semin Oncol, 1999,26(5 suppl 14):43-51.
  • 2[2]Johmson RC,Ricci A Jr,Cartun RW,et al.p185HER-2 overexpression in human breast cancer using molecular and immunohistochemical methods[J]. Cancer-Invest.2000; 18(4) :336 - 342.
  • 3[3]Maguire HC, Green MI .The neu(c-erbB-2) oncogene[J]. Semin oncol, 1989,16(2): 148 - 155.
  • 4[4]Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer:Prognostic factor, predictive factor and target for therapy[J]. Stem cella, 1998, 16(6) :413 - 28.
  • 5[5]Hunter H. A thousand and a protein kineses [J ]. Cell, 1987, 50(6): 823 - 829.
  • 6[6]Nakabeppu Y, Ryder K, Nathan S. DNA binding activities of three murine jun proteins: Stimulation by fos[J]. Call, 1998, 55(5) :907-915.
  • 7[7]Pegram MD,Pauletti G, Slaraon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy[J] .Breast Cancer Res Treat,1998; 52(1-3): 65-77.
  • 8[8]Pegram MD,Pauletti G,Slamon DJ.HER-2/neu as a predictive marker of response to breast cancer therapy[J]. Breast Cancer Res Treat,1998, 52(1 - 3): 65 - 77.
  • 9[9]Slamon DJ, Clark GM,Wong-SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 1987, 235(4785): 177-182.
  • 10[10]May E, Mouriesse H, May Levin F, et al. Human breast cancer:identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c - erbB-2 overexpression[J].BrJ Cancer, 1990, 62(3): 430-435.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部